13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001848809
Total reported value
$164.2M
$164.2M
49 檔
27.3%
At the close of Q3 2025, Velan Capital Investment Management LP disclosed equity holdings valued at approximately $164.2M, spread across 49 reported holdings.
In Q3 2025, Velan Capital Investment Management LP displayed an active expansion posture, initiating 17 new positions and adding to 18 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including HRTX, CDTX, TARA) accounted for 27.3% of total reported equity market value during Q3 2025.
Top New Position Initiated
CDTX
市值: $10.4M
Top Position Liquidated / Trimmed
ACELYRIN INC
前期市值: $8.3M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HRTX | Heron Therapeutics Inc | Stock-Other | 10.36% | -2.11% | +25.28% | |
| 2 | CDTX | Cidara Therapeutics Inc | Stock-Other | 9.75% | — | +8.40% | |
| 3 | TARA | Protara Therapeutic Inc | Stock-Other | 8.74% | -2.63% | — | |
| 4 | RZLT | Rezolute Inc | Stock-Other | 6.62% | +0.95% | — | |
| 5 | PRAX | Praxis Precision Medicines I | Stock-Other | 6.61% | -2.24% | -11.07% | |
| 6 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 6.25% | -0.01% | +0.57% | |
| 7 | JSPR | Jasper Therapeutics Inc | Stock-Other | 5.83% | -0.78% | +86.10% | |
| 8 | ABVX | Abivax Sa-adr | Stock-Other | 5.13% | -0.04% | — | |
| 9 | NSPR | Inspiremd Inc | Stock-Other | 4.85% | -2.08% | +137.13% | |
| 10 | ✓ | Stock-Other | 4.02% | — | — | ||
| 11 | ALMS | Alumis Inc | Stock-Other | 3.55% | — | -41.59% | |
| 12 | LNTH | Lantheus Holdings Inc | Stock-Healthcare | 3.54% | — | — | |
| 13 | AVTX | Avalo Therapeutics Inc | Stock-Other | 3.15% | +1.92% | +70.12% | |
| 14 | STRO | Sutro Biopharma, Inc. | Stock-Other | 2.54% | — | +1.96% | |
| 15 | EPRX | Eupraxia Pharmaceuticals Inc | Stock-Other | 1.95% | -0.18% | — | |
| 16 | RAPT | Rapt Therapeutics Inc | Stock-Other | 1.94% | — | — | |
| 17 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.88% | -0.02% | — | |
| 18 | TRVI | Trevi Therapeutics Inc | Stock-Other | 1.76% | — | — | |
| 19 | QURE | uniQure N.V. | Stock-Other | 1.75% | — | — | |
| 20 | VRDN | Viridian Therapeutics Inc | Stock-Other | 1.75% | -1.01% | — | |
| 21 | EDSA | Edesa Biotech Inc | Stock-Other | 1.60% | +1.39% | — | |
| 22 | TELA | Tela Bio Inc | Stock-Other | 1.05% | — | — | |
| 23 | ELDN | Eledon Pharmaceuticals Inc | Stock-Other | 0.84% | — | +2.36% | |
| 24 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 0.72% | — | +3.39% | |
| 25 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.60% | -0.36% | — | |
| 26 | TRML | Tourmaline Bio Inc | Stock-Other | 0.26% | — | -98.53% | |
| 27 | CTMX | Cytomx Therapeutics Inc | Stock-Other | 0.24% | -1.32% | +6.67% | |
| 28 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.23% | +0.04% | — | |
| 29 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 0.21% | -0.26% | EXIT | |
| 30 | OVID | Ovid Therapeutics Inc | Stock-Other | 0.20% | -0.01% | — | |
| 31 | GOSS | Gossamer Bio Inc | Stock-Other | 0.17% | — | -6.67% | |
| 32 | ALEC | Alector Inc | Stock-Other | 0.15% | — | — | |
| 33 | DSGN | Design Therapeutics Inc | Stock-Other | 0.14% | -0.13% | EXIT | |
| 34 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 0.14% | — | — | |
| 35 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.14% | +0.08% | +60.00% | |
| 36 | ERAS | Erasca Inc | Stock-Other | 0.13% | — | — | |
| 37 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.12% | — | — | |
| 38 | PYXS | Pyxis Oncology Inc | Stock-Other | 0.11% | — | +37.50% | |
| 39 | IMNM | Immunome Inc | Stock-Other | 0.11% | -0.01% | — | |
| 40 | DTIL | Precision Biosciences Inc | Stock-Other | 0.10% | +0.05% | — | |
| 41 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.10% | — | — | |
| 42 | GERN | Geron CORP | Stock-Other | 0.10% | — | +14.29% | |
| 43 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.10% | -0.03% | — | |
| 44 | CNTX | Context Therapeutics Inc | Stock-Other | 0.09% | -0.14% | — | |
| 45 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.09% | — | — | |
| 46 | REPL | Replimune Group Inc | Stock-Other | 0.08% | +0.03% | -89.08% | |
| 47 | IMMX | Immix Biopharma Inc | Stock-Other | 0.07% | +2.59% | +40.00% | |
| 48 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 0.06% | — | — | |
| 49 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 0.05% | -0.06% | EXIT |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RZLT | Rezolute Inc | +5.4% | — | Add |
| 2 | MLYS | Mineralys Therapeutics Inc | +3.8% | +0.57% | Add |
| 3 | NSPR | Inspiremd Inc | +2.4% | +137.13% | Add |
| 4 | AVTX | Avalo Therapeutics Inc | +2.2% | +70.12% | Add |
| 5 | STRO | Sutro Biopharma, Inc. | +1.9% | +1.96% | Add |
| 6 | TARA | Protara Therapeutic Inc | +1.4% | — | Add |
| 7 | CRBP | Corbus Pharmaceuticals Holdi | +0.4% | +3.39% | Add |
| 8 | CTMX | Cytomx Therapeutics Inc | +0.2% | +6.67% | Add |
| 9 | OVID | Ovid Therapeutics Inc | +0.2% | — | Add |
| 10 | TELA | Tela Bio Inc | +0.1% | — | Unchanged |
| 11 | 430 | Terns Pharmaceuticals Inc | +0.1% | — | Add |
| 12 | GOSS | Gossamer Bio Inc | +0.1% | -6.67% | Trim |
| 13 | DSGN | Design Therapeutics Inc | +0.1% | — | Add |
| 14 | ALEC | Alector Inc | +0.1% | — | Unchanged |
| 15 | VTYXUSD | Ventyx Biosciences Inc | +0.1% | — | Unchanged |
| 16 | ERAS | Erasca Inc | +0.1% | — | Add |
| 17 | TENX | Tenax Therapeutics Inc | 0% | — | Unchanged |
| 18 | LRMR | Larimar Therapeutics Inc | 0% | — | Add |
| 19 | CNTX | Context Therapeutics Inc | 0% | — | Add |
| 20 | ✓ | Proqr Therapeutics N.v. | 0% | — | Unchanged |
| 21 | PMVP | Pmv Pharmaceuticals Inc | 0% | — | Unchanged |
| 22 | ACRS | Aclaris Therapeutics Inc | — | — | Trim |
| 23 | WVE | Wave Life Sciences Ltd. | 0% | — | Add |
| 24 | EDSA | Edesa Biotech Inc | -0.1% | — | Unchanged |
| 25 | ELDN | Eledon Pharmaceuticals Inc | -0.3% | +2.36% | Add |
| 26 | JSPR | Jasper Therapeutics Inc | -0.5% | +86.10% | Add |
| 27 | PRAX | Praxis Precision Medicines I | -0.6% | -11.07% | Trim |
| 28 | IMNM | Immunome Inc | -1% | — | Trim |
| 29 | GERN | Geron CORP | -1% | +14.29% | Trim |
| 30 | REPL | Replimune Group Inc | -1.8% | -89.08% | Trim |
| 31 | HRTX | Heron Therapeutics Inc | -5.5% | +25.28% | Add |
| 32 | TRML | Tourmaline Bio Inc | -6.9% | -98.53% | Trim |
| 33 | CDTX | Cidara Therapeutics Inc | — | NEW | New buy |
| 34 | ✓ | Acelyrin Inc | — | EXIT | Sold out |
| 35 | SWTXUSD | Springworks Therapeutics Inc | — | EXIT | Sold out |
| 36 | VRNA | Verona Pharma PLC - Adr | — | EXIT | Sold out |
| 37 | ABVX | Abivax Sa-adr | — | NEW | New buy |
| 38 | ZVRA | Zevra Therapeutics Inc | — | EXIT | Sold out |
| 39 | LQDA | Liquidia CORP | — | EXIT | Sold out |
| 40 | ✓ | — | NEW | New buy | |
| 41 | ALMS | Alumis Inc | — | NEW | New buy |
| 42 | LNTH | Lantheus Holdings Inc | — | NEW | New buy |
| 43 | SCPH | Scpharmaceuticals Inc | — | EXIT | Sold out |
| 44 | EPRX | Eupraxia Pharmaceuticals Inc | — | NEW | New buy |
| 45 | RAPT | Rapt Therapeutics Inc | — | NEW | New buy |
| 46 | SNDX | Syndax Pharmaceuticals Inc | — | NEW | New buy |
| 47 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 48 | QURE | uniQure N.V. | — | NEW | New buy |
| 49 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 50 | TIL | Instil Bio Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Velan Capital Investment Management LP reported a total U.S. public equity portfolio value of $164.2M across 49 disclosed positions in Q3 2025.
During Q3 2025, Velan Capital Investment Management LP's top holdings by market value included HRTX (10.4%)、CDTX (9.8%)、TARA (8.7%). The largest single position, HRTX, represented 10.4% of total portfolio value.
In Q3 2025, Velan Capital Investment Management LP made 57 total portfolio adjustments, initiating 17 new buys, adding to 18 positions, trimming 7 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.